+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Analysis Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102668
Systemic sclerosis (SS) in interstitial lung disease (ILD) is a serious condition that significantly impacts patient health, contributing to high morbidity and mortality rates. The prevalence of systemic sclerosis in interstitial lung disease varies widely, ranging from 25% to 95%, depending on the detection methods employed. Despite existing treatment options such as immunosuppressive therapies, there is a significant unmet clinical need for more effective treatments to slow disease progression. The increasing focus on precision medicine and targeted therapies is expected to drive advancements in the drug pipeline, offering hope for better management and improved patient outcomes in the coming years.

Report Coverage

The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report by the publisher gives comprehensive insights into systemic sclerosis (SS) in interstitial lung disease (ILD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for systemic sclerosis (SS) in interstitial lung disease (ILD). The systemic sclerosis (SS) in interstitial lung disease (ILD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with systemic sclerosis (SS) in interstitial lung disease (ILD) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic sclerosis (SS) in interstitial lung disease (ILD).

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Outlook

Systemic sclerosis (SS) in interstitial lung disease (ILD) is a serious complication where inflammation and scarring (fibrosis) of lung tissue result in progressive loss of lung function. The condition arises when the body's immune system mistakenly attacks healthy lung tissue, causing the buildup of fibrous tissue that interferes with normal lung function. It can significantly impair the ability to breathe, contributing to morbidity and mortality.

Systemic sclerosis (SS) in interstitial lung disease (ILD) treatment typically includes immunosuppressive medications to manage inflammation, corticosteroids to reduce immune system activity, and antifibrotic agents to slow lung tissue scarring. In recent years, novel therapies targeting fibrosis and immune modulation have been actively researched, offering hope for improved outcomes and better management of disease progression.

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) - Epidemiology

The prevalence of systemic sclerosis (SS) in interstitial lung disease (ILD) varies globally, ranging from 25% to 90%. Epidemiological studies highlight ethnic and regional differences, with African Americans and certain Asian populations showing a higher incidence. In comparison to Caucasians (38%), African Americans (54%) are diagnosed more commonly. Regional differences further highlight a higher prevalence in Central and Eastern Europe, as well as some parts of Asia.

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total systemic sclerosis (SS) in interstitial lung disease (ILD) clinical trials.

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for systemic sclerosis (SS) in interstitial lung disease (ILD).

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for systemic sclerosis (SS) in interstitial lung disease (ILD) report insights to include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) clinical trials:
  • GlaxoSmithKline
  • aTyr Pharma, Inc.
  • Prometheus Biosciences, Inc.
  • Changchun GeneScience Pharmaceutical Co., Ltd.
  • Genentech, Inc.
  • Bristol-Myers Squibb
  • Sanofi
  • Boehringer Ingelheim
  • ICON plc

Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for systemic sclerosis (SS) in interstitial lung disease (ILD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates.

Belimumab

A Phase 2/3 study, sponsored by GlaxoSmithKline, is investigating the efficacy and safety of belimumab in adults with systemic sclerosis-associated interstitial lung disease. The objective of this Phase 2/3 study is to evaluate belimumab's effect on lung function and extra-pulmonary manifestations. The study is expected to be completed by July 2027, with 300 participants enrolled.

Tulisokibart

The Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in subjects with systemic sclerosis-associated interstitial lung disease is being sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. This double-blind, randomized, placebo-controlled study aims to assess the safety and efficacy of Tulisokibart. The study is expected to be completed by June 2029, with an estimated 152 participants.

Reasons To Buy This Report

The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for systemic sclerosis (SS) in interstitial lung disease (ILD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline insights.

Key Questions Answered in the Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) - Pipeline Insight Report

  • Which companies/institutions are leading the systemic sclerosis (SS) in interstitial lung disease (ILD) drug development?
  • What is the efficacy and safety profile of systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline drugs?
  • Which company is leading the systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline development activities?
  • What is the current systemic sclerosis (SS) in interstitial lung disease (ILD) commercial assessment?
  • What are the opportunities and challenges present in the systemic sclerosis (SS) in interstitial lung disease (ILD) drug pipeline landscape?
  • What is the efficacy and safety profile of systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline drugs?
  • Which company is conducting major trials for systemic sclerosis (SS) in interstitial lung disease (ILD) drugs?
  • Which companies/institutions are involved in systemic sclerosis (SS) in interstitial lung disease (ILD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in systemic sclerosis (SS) in interstitial lung disease (ILD)?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD)
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD)
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD): Epidemiology Snapshot
5.1 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Incidence by Key Markets
5.2 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) - Patients Seeking Treatment in Key Markets
6 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD): Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD): Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD), Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Belimumab
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Tocilizumab|Drug: Nintedanib
10.2.3 Drug: Rituximab
10.2.4 Other Drugs
11 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Tulisokibart
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: Mycophenolate Mofetil
11.2.3 Drug: efzofitimod 450 mg|Drug: efzofitimod 270 mg
11.2.4 Drug: Vixarelimab
11.2.5 Drug: Amlitelimab|Drug: BI 1015550
11.2.6 Other Drugs
12 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD), Key Drug Pipeline Companies
14.1 GlaxoSmithKline
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 aTyr Pharma, Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Prometheus Biosciences, Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Changchun GeneScience Pharmaceutical Co., Ltd.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Genentech, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Bristol-Myers Squibb
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Sanofi
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Boehringer Ingelheim
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 ICON plc
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products